{
    "organizations": [],
    "uuid": "dbd6e214fe07b5fe74b6fe87a875a0b2fe5d7eea",
    "author": "Gerrard Cowan",
    "url": "https://www.wsj.com/articles/cancer-focused-etf-tops-the-charts-1523239380",
    "ord_in_thread": 0,
    "title": "Cancer-Focused ETF Tops the Charts",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "A fund focused on cancer-treating immunotherapy drugs is one of the year’s best-performing nonleveraged equity ETFs, thanks to technological breakthroughs and increased merger-and-acquisition activity in the sector.\nThe $64 million Loncar Cancer Immunotherapy exchange-traded fund (CNCR) invests in companies developing therapies that aim to harness the body’s immune system to fight cancer. Its holdings range from specialized firms such as Atara Biotherapeutics to drug giants such as AstraZeneca.\n... To Read the Full Story Subscribe Sign In",
    "published": "2018-04-09T06:03:00.000+03:00",
    "crawled": "2018-04-09T09:48:20.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "fund",
        "focused",
        "immunotherapy",
        "drug",
        "one",
        "year",
        "nonleveraged",
        "equity",
        "etf",
        "thanks",
        "technological",
        "breakthrough",
        "increased",
        "activity",
        "sector",
        "million",
        "loncar",
        "cancer",
        "immunotherapy",
        "fund",
        "cncr",
        "invests",
        "company",
        "developing",
        "therapy",
        "aim",
        "harness",
        "body",
        "immune",
        "system",
        "fight",
        "cancer",
        "holding",
        "range",
        "specialized",
        "firm",
        "atara",
        "biotherapeutics",
        "drug",
        "giant",
        "astrazeneca",
        "read",
        "full",
        "story",
        "subscribe",
        "sign"
    ]
}